In:
International Journal of Cancer, Wiley, Vol. 145, No. 5 ( 2019-09), p. 1312-1324
Abstract:
What's new? Despite encouraging results with anti‐CD19 chimeric antigen receptor T (CART) cell therapy for B cell malignancies, clinical outcome could still be improved by optimization of the CART cell generation process. Here, the authors show that ex vivo PI3Kδ inhibition by the B cell malignancy drug idelalisib during CART cell generation can increase the proportion of less‐differentiated T cells and lead to a less exhausted T cell phenotype. Idelalisib optimized the phenotype of CART cells derived from chronic lymphocytic leukemia (CLL) patients. This study thus provides important novel and potentially practice‐changing findings for CART cell generation and expansion, especially for CLL patients.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8